BioStock: Ultimovacs strengthens clinical validation of UV1 in Q2
Q2 was all about increasing momentum in the clinic for Norwegian Ultimovacs. The company’s universal cancer vaccine UV1 has progressed steadily in one of its phase I trials and in its four phase II trials. CEO Carlos de Sousa joined BioStock for a comment on the newly released report.
Read the interview with Carlos de Sousa at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.